Product Information
FYCOMPA 12 MG TABLET is a brand product labeled by Catalyst Pharmaceuticals, Inc., priced at $39.1096 per EA under NDC 69616028230. Its NADAC has been published 139 times since Feb 7, 2024.
FDA first approved this application on Oct 22, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12 mg/1
Manufacturer
Catalyst Pharmaceuticals, Inc.NDC
69616028230
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PERAMPANELApproval Type
New Drug (NDA)
FDA Application
NDA202834FDA Approved
10/22/2012
TE Code
AB
On Market Since
1/2/2024
Pharmacological Classes
Price Statistics
The NADAC for FYCOMPA 12 MG TABLET has been published 139 times since Feb 7, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $39.1096 per EA |
|---|---|
| All-time high | $39.4499 (May 15, 2024) |
| All-time low | $39.0776 (Aug 19, 2026) |
| 52-week high | $39.2369 |
| 52-week low | $39.0776 |
| Median price | $39.2369 |
| Average price | $39.2322 |
| Largest weekly change | -0.8% (May 22, 2024) |
| Weeks tracked | 139 |
| Tracking since | Feb 7, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Catalyst Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
perampanel market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Noncompetitive AMPA Glutamate Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FYCOMPA 12 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FYCOMPA 12 MG TABLET, manufactured by Catalyst Pharmaceuticals, Inc., is $39.1096 per EA (NDC 69616028230), effective Sep 30, 2026.
How has the price of FYCOMPA 12 MG TABLET changed over time?
Over the history we have for it, the NADAC for FYCOMPA 12 MG TABLET has held within roughly two percent of its current level. It has been tracked across 139 weekly CMS publications since Feb 7, 2024.
What are the highest and lowest recorded NADAC prices for FYCOMPA 12 MG TABLET?
Since Feb 7, 2024, the NADAC for FYCOMPA 12 MG TABLET has ranged from a low of $39.0776 (Aug 19, 2026) to a high of $39.4499 (May 15, 2024), with a median of $39.2369 per EA.
Are there cheaper alternatives to FYCOMPA 12 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as FYCOMPA 12 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures FYCOMPA 12 MG TABLET?
FYCOMPA 12 MG TABLET (NDC 69616028230) is labeled by Catalyst Pharmaceuticals, Inc., and CMS classifies it as a brand product.